**November 13, 2013:** The CRCPD is extending the period for registering unwanted sources into the SCATR program for a roundup occurring in 2014. The following letter is being mailed to each licensee: [CRCPD SCATR Letter](#)

**October 30, 2013:** The FDA has approved Vizamyl (flutemetamol F 18 injection), a radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia. Here is to the FDA approval package: [FDA's Vizamyl Approval](#)

**June 17, 2013:** The Source Collection and Threat Reduction Program (SCATR) administered by the Conference of Radiation Control Program Directors (CRCPD) is providing sealed source licensees in states which do not have access to an in-Compact low-level radioactive waste disposal facility an opportunity to dispose of certain unwanted radioactive sealed sources. CRCPD is offering generators who participate in this limited-time opportunity financial assistance equal to 50% of the cost of collection, processing, and disposal. Generators must register their sources with the Offsite Source Recovery Project (OSRP) [OSRP](#) by June 30, 2013 to qualify for participation in this cost-shared disposal effort.

**May 16, 2013:** On May 15th the FDA approved the use of Xofigo (Ra-223 dichloride) for the treatment of men with symptomatic late-stage (metastic) castration-resistant prostate cancer that has spread to the bones but not other organs. Bayer has the marketing rights to Xofigo. The use of Xofigo will be under 12VAC5-481-1950 and the Authorized Users must be approved for this use. The FDA approval information can be found here: [FDA Ra-223/Xofigo Information](#). If you have any other questions regarding the use of Xofigo, please contact us.

**May 9, 2013:** On May 7, 2013 the NRC issued FSME-13-041 titled "Notice of an upcoming webinar and request for comments on consideration of rulemaking to address prompt remediation of residual radioactivity during operations." This document states the webinar will be held on June 4th from 12 pm until 3 pm. For more information, the document can be found here: [FSME-13-041](#)